Marco Prado, Vania Prado and their colleagues at the Schulich School of Medicine & Dentistry’s Robarts Research Institute, looked at changes related to a neurotransmitter or chemical messenger, named acetylcholine (ACh), and the kinds of memory problems associated with it. The research is now published online by PNAS.
The researchers, including first author Amanda Martyn, created a mouse line that doesn’t have enough ACh being secreted by neurons in the same brain regions affected by Alzheimer’s disease. They found this neurochemical failure caused problems with spatial memory, the stored information that is needed for navigating one’s environment. For instance, the memory needed to drive across town. They also found the reduction of ACh led to hyperactivity, which many patients with Alzheimer’s experience.
“Once we reproduced that neurochemical failure, we asked, ‘how does that affect spatial memory, how does it affect learning?’ We found mice that don’t have that particular chemical messenger in specific areas of the brain, have problems with spatial memory, for example,” says Marco Prado. “This reveals specific types of cognitive deficits that we can hope to improve with drugs that boost this chemical messenger.”
This research was funded by the Canadian Institutes of Health Research and PrioNet Canada. Alzheimer’s disease affects 5.4 million Americans and more than 500,000 Canadians, and those numbers are expected to climb dramatically as baby boomers age.
Media contact: Kathy Wallis, Media Relations Officer, Schulich School of Medicine & Dentistry, Western University, 519-661-2111 ext. 81136